Recursion Announces Board Transition

Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current term through June ...

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 ...

Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast

Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets ...
Seeking Alpha

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...
Seeking Alpha

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...
The National Law Review

Recursion to Participate in Upcoming Investor Conference

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...
AOL

This $4 Stock Could Be Your Ticket to Millionaire Status

What's the best next use of artificial intelligence (AI)? Plenty of people would say drug development. And they'd arguably be right. That's not something for down the road, though, when AI is more ...
Nasdaq

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Nasdaq

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...